http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Ca
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
-
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
-
Cue Biopharma Inc. (CUE) Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
-
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
-
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
-
Cue Biopharma to Present at Two September 2022 Scientific Conferences
-
Cue Biopharma to Present at Two September 2022 Scientific Conferences
-
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers
-
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers
-
Cue Biopharma Reports Second Quarter 2022 Financial Results
-
Cue Biopharma Reports Second Quarter 2022 Financial Results
-
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
-
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
-
Cue Biopharma to Present at the JMP Securities Life Sciences Conference
-
Cue Biopharma to Present at the JMP Securities Life Sciences Conference
-
Cue Biopharma to Present at the Jefferies Healthcare Conference
-
Cue Biopharma to Present at the Jefferies Healthcare Conference
-
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Cue Biopharma Inc. (CUE) Announces FDA Acceptance of IND for CUE-102
-
Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers
-
Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers
-
Cue Biopharma Reports First Quarter 2022 Financial Results
-
Cue Biopharma Reports First Quarter 2022 Financial Results
-
Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference
-
Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference
-
Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress
-
Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress
-
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting
-
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting
-
Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patien
-
Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patien
-
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials
-
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials
-
Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102
-
Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102
-
Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer
-
Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer
-
Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit
-
Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit
-
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference
-
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference
-
Cue Biopharma (CUE) Presents Updated Data from Lead Program CUE-101 for Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at SITC
-
Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of C
-
Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of C
